Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:49 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

NCT04816604 · Gossamer Bio USA, Inc. · PHASE2 · terminated · last registry update 2026-11-05 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

Kind	Quote	Our category	Source
Stated	“Enrollment has declined and remaining participants have been on study more than three years. Continued study visits/data collection are no longer considered necessary. This is not expected to affect study interpretation or the overall benefit-risk.”	–	Registry record, Gossamer Bio USA, Inc.

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against KIT within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

Internal portfolio and board discussions
Unpublished trial data and interim analyses
Terms of any partner or licence decision